Yindymarra (to Honour, Respect) Aboriginal Experiences In The Conduct Of Health Research: The Development Of Practical Recommendations To Enhance The Uptake Of Ethical Research Guidelines.
Funder
National Health and Medical Research Council
Funding Amount
$1,015,166.00
Summary
Ethical, high quality research is needed to reduce the health gap between Aboriginal and non-Aboriginal Australians. Currently, there is no critical analysis of the uptake of ethical guidelines. This study will investigate the experiences of Aboriginal communities and Aboriginal health researchers at a national level. Collected data will inform a nationally endorsed set of practical recommendations to guide future Aboriginal health research.
A Roadmap For Aboriginal And Torres Strait Islander Adolescent Health: Defining Priority Health Needs And Actions Through The Empowerment & Capacity Development Of Young People.
Funder
National Health and Medical Research Council
Funding Amount
$2,002,448.00
Summary
A third of the Indigenous population are adolescents, their health central to cultural continuity and health equity. Yet priority health needs and evidence-based responses for Indigenous adolescents remain poorly defined, a barrier to effective policy. The project is significant because it will establish a roadmap to guide actions around Indigenous adolescent health. It will also result in a network of engaged and up-skilled Indigenous young people who can drive implementation.
Antibiotic Potentiators As An Alternative Therapeutic Option For The Treatment Of Extensively Drug-resistant Gram-negative Infections
Funder
National Health and Medical Research Council
Funding Amount
$856,858.00
Summary
Antibiotic mono-therapies are increasingly ineffective for hard-to-treat bacterial infections, forcing clinicians to rely on combinations of antibiotics. Our project has identified compounds that have weak to no antimicrobial potency in their own right, yet when combined with an existing antibiotic they potentiate its activity and restore its ability to treat resistant infections. These antibiotic potentiators are exciting alternatives to current therapies with reduced risk of induced resistance
Osteoarthritis Compass: Predicting Personalized Disease Onset And Progression With Future Capacity For Clinical Use.
Funder
National Health and Medical Research Council
Funding Amount
$860,231.00
Summary
Knee osteoarthritis (OA) is common, painful, and costly. General guidelines for knee OA management exist but cannot be personalized to the patient. New computer modelling methods enable prediction of knee OA onset and progression on a patient by patient basis but need further testing. Our aims are to 1) apply these new computer modelling methods to legacy datasets acquired from patient groups at risk of, and with, knee OA, and 2) make these models simple and fast enough to be clinically useful.
Improving Clinical Outcomes Of Antimicrobial Resistant Infections With A Drug-free Intervention
Funder
National Health and Medical Research Council
Funding Amount
$999,581.00
Summary
Superbugs, or antimicrobial-resistant pathogens, cause recurring infections and non-healing wounds after surgery as existing therapies fail to effectively kill them. We will develop a medical device to fight superbugs with UV light that is effective against bacteria and fungi without causing harm to human cells. This could eradicate superbugs at infection sites, aid wound healing and actively improve health outcomes after surgery.
Hijacking A Death Switch In Pancreatic And Lung Cancer Cells To Develop A Novel Therapy
Funder
National Health and Medical Research Council
Funding Amount
$738,947.00
Summary
Pancreatic (PC) and lung (LC) cancer have a high mortality rate and poor response to current treatments. We have identified a protein whose inhibition in both PC and LC cells sensitises them to a cancer-cell specific therapy called TRAIL and switches signals that normally promote tumour growth into tumour death signals. This project aims to develop a novel therapeutic that inhibits our target and delivers TRAIL to PC and LC tumours, and could potentially improve survival for PC and LC patients.
Therapeutic Induction Of Tertiary Lymph Nodes In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$995,010.00
Summary
Immunotherapy has been an important recent advance in cancer treatment by using the body's own immune cells to fight cancer. Although there have been unprecedented dramatic results, not all patients benefit, and most benefits are temporary. The cellular environment in which cancers are embedded is crucial for controlling treatment success. We aim to apply novel 'precision' therapies to this environment to expose the cancer and enable attack by immune cells for improved immunotherapy.
Developing Smart Nanomedicine To Enable Advanced Diagnosis And Stimuli-responsive Treatment For Atherosclerosis And Thrombosis
Funder
National Health and Medical Research Council
Funding Amount
$523,342.00
Summary
The early detection and accurate characterization of life-threatening diseases such as cardiovascular diseases are critical to the design of treatment. A therapeutic approach that provides an efficient treatment with minimal side-effects is highly desired by both patients and healthcare systems. This project aims to develop smart nanomedicine with incorporated diagnostic sensor and external stimuli-responsive treatment mechanisms for cardiovascular diseases.
Improving Cardiac Valve Implant Outcomes With Advanced Computer Simulation
Funder
National Health and Medical Research Council
Funding Amount
$593,367.00
Summary
This project focuses on improving heart valve procedures, specifically focusing on new transcatheter techniques of heart valve implantation. The research uses advanced imaging and computer simulation techniques to predict the outcome and improve minimally invasive heart procedures.
New Therapies Requiring Ultra Large Scale Monoclonal Ab Production In Microalgae
Funder
National Health and Medical Research Council
Funding Amount
$630,089.00
Summary
Monoclonal antibodies target pathogens and molecules with exquisite specificity, and are essential for therapeutics and diagnostics. They are currently made using high-tech/limited-capacity mammalian cell cultures which limit them to low-dose applications. We aim to enable new, high-dose antibody therapies (e.g. antiviral treatments, passive immunisation) via rapid, low-cost, dramatically larger-scale production of valuable medicinal antibodies in a photosynthetic-driven, green algae system.